2,2-Didecoxy-4-(4-phenylpiperidin-4-yl)butan-1-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,2-Didecoxy-4-(4-phenylpiperidin-4-yl)butan-1-amine
• 英文别名: 2,2-didecoxy-4-(4-phenylpiperidin-4-yl)butan-1-amine
• 化学式: C₃₅H₆₄N₂O₂
• 分子量: 544.9
• InChiKey: NUNAIETZMDXLNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.5
• 重原子数：
  39
• 可旋转键数：
  25
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  56.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV
  申请人：Gilead Sciences, Inc.

  公开号：EP3166607A1

  公开（公告）日：2017-05-17
• MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV
  申请人：Gilead Sciences, Inc.

  公开号：EP3349757A1

  公开（公告）日：2018-07-25
• [EN] METHODS AND COMPOSITIONS FOR LOCALIZED DELIVERY OF AGENTS TO HIV-INFECTED CELLS AND TISSUES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR L'ADMINISTRATION LOCALISÉE D'AGENTS À DES CELLULES ET DES TISSUS INFECTÉS PAR LE VIH
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2014074952A1

  公开（公告）日：2014-05-15

  The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes.
• [EN] MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV<br/>[FR] MODULATEURS DE RÉCEPTEURS DE TYPE TOLL POUR LE TRAITEMENT DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2016007765A1

  公开（公告）日：2016-01-14

  Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula (II); and pharmaceutically acceptable salts thereof, useful in treating HIV infections.
• [EN] MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV<br/>[FR] MODULATEURS DE RÉCEPTEURS DE TYPE TOLL POUR LE TRAITEMENT DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2017048727A1

  公开（公告）日：2017-03-23

  Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR8 and pharmaceutically acceptable salts thereof, useful in treating HIV infections.